n e w s r e l e a s e Exhibit 99.2 Humana Inc. 500 West Main Street P.O. Box 1438 Louisville, KY 40202 http://www.humana.com FOR MORE INFORMATION CONTACT: Lisa Stoner Humana Investor Relations (502) 580-2652 e-mail: LStamper@humana.com Mark Taylor Humana Corporate Communications (317) 753-0345 e-mail: MTaylor108@humana.com Humana Reports Third Quarter 2025 Financial Results; Affirms Full Year 2025 Adjusted EPS Guidance LOUISVILLE, KY (November 5, 2025) – Humana Inc. (NYSE: HUM) today reported consolidated p ...

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share (EPS) for the quarter ended September 30, 2025 (3Q25) versus the quarter ended September 30, 2024 (3Q24) and for the nine months ended September 30, 2025 (YTD 2025) versus the nine months ended September 30, 2024 (YTD 2024) as noted in the tables below. Consolidated income before income taxes and equity in net losses (pretax results) in millions 3Q25 (a) 3Q24 (a) Y. ...

Earnings Results - Humana Inc. is set to release its third-quarter earnings results on November 5, with expected earnings of $2.82 per share, a decrease from $4.16 per share in the same period last year [1] - The consensus estimate for Humana's quarterly revenue is $32.01 billion, up from $29.4 billion a year earlier [1] Dividend Announcement - On October 28, Humana declared a cash dividend of 88.5 cents per share to stockholders [2] - Following the announcement, Humana's shares rose by 0.7%, closing at $281.87 [2] Analyst Ratings and Price Targets - B of A Securities maintained a Neutral rating and raised the price target from $280 to $300 [4] - Mizuho maintained an Outperform rating and increased the price target from $300 to $345 [4] - Barclays maintained an Equal-Weight rating and cut the price target from $315 to $245 [4] - RBC Capital maintained an Outperform rating and raised the price target from $283 to $322 [4] - Argus Research reiterated a Hold rating with a price target of $281.99 [4]

RT Dutch Rojas (@DutchRojas)7 health insurance CEOs made $335 million in 2022. That’s extraction.When you outlaw competition, via political donations this is what happens:Certificate of Need laws block new entrants.Stark and Section 6001 ban physician-owned systems.Site-neutral rules reward consolidation.So insurers and “nonprofit” health systems keep printing money while physicians fight for scraps.If doctors could build and own health systems again, these CEOs wouldn’t be making yacht money from your prem ...

Core Viewpoint - Humana (HUM) shares have recently declined by 5.2% over the past four weeks, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottoming out, suggesting that selling pressure may be exhausting. This pattern is characterized by a small candle body and a long lower wick, indicating that buyers are starting to emerge after a downtrend [4][5]. - The occurrence of a hammer pattern at the bottom of a downtrend signals that bears may be losing control, which could lead to a trend reversal [5]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for Humana, which is a bullish indicator. Over the last 30 days, the consensus EPS estimate for the current year has increased by 0.3%, indicating that analysts expect better earnings than previously predicted [7][8]. - Humana currently holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks. Stocks with a Zacks Rank of 1 or 2 typically outperform the market, further supporting the potential for a trend reversal [9][10].

Wall Street analysts expect Humana (HUM) to post quarterly earnings of $2.91 per share in its upcoming report, which indicates a year-over-year decline of 30.1%. Revenues are expected to be $31.98 billion, up 9.1% from the year-ago quarter.The current level reflects a downward revision of 2.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a company's ...

Don’t miss your chance to be part of the Forbes Healthcare Summit in NYC on 12/4. Join healthcare industry leaders and speakers from Humana, CVS Health, Epic and other top companies. With limited spots and high demand, now’s the time to apply to attend. Check out the incredible speaker lineup today! https://t.co/1ay9z4AxlP ...

Core Insights - CarePlus has announced its Medicare Advantage plan offerings for the year 2026, indicating a strategic move to enhance its product portfolio in the healthcare sector [1] Group 1 - The announcement reflects CarePlus's commitment to expanding its services and catering to the needs of Medicare beneficiaries [1] - The new plan offerings are expected to provide enhanced benefits and options for members, aligning with industry trends towards more comprehensive healthcare solutions [1] - This initiative may position CarePlus favorably in a competitive market, as it seeks to attract more enrollees through improved plan features [1]

Core Insights - Humana Inc. (NYSE: HUM) has experienced a significant stock rally, with a five-day winning streak resulting in a cumulative gain of 13%, adding approximately $4.0 billion in market value [2] - The current market capitalization of Humana is around $36 billion, and the stock is 17.6% above its value at the end of 2024, outperforming the S&P 500's year-to-date return of 14.5% [2] - The recent surge in Humana's stock price is attributed to strategic partnerships, including one with Providence Health System for data exchange and a continuation of co-branded Medicare Advantage plans with USAA featuring $0 copays for mental health services in 2026 [2] Stock Performance Analysis - The performance of HUM stock has been compared to the S&P 500 index, indicating a positive momentum that may signal growing investor confidence [5] - There are currently 191 S&P constituents with three or more consecutive days of gains, highlighting a broader trend in the market [6] Investment Considerations - While HUM stock appears attractive due to its recent performance, investing in a single stock carries inherent risks, and a diversified approach is recommended [4][7] - The Trefis High Quality Portfolio, in collaboration with Empirical Asset Management, aims to provide better returns with less risk compared to the benchmark index, particularly during market downturns [4][7]

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana announces 2026 Medicare Advantage plans designed with veterans in mind. Humana USAA Honor Giveback Plans elevate mental health support. ...